Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Change in Acquisitions & Divestments (2020 - 2023)

Cullinan Therapeutics (CGEM) has 4 years of Change in Acquisitions & Divestments data on record, last reported at $117.5 million in Q4 2023.

  • For Q4 2023, Change in Acquisitions & Divestments fell 11.4% year-over-year to $117.5 million; the TTM value through Dec 2023 reached $409.4 million, up 16.0%, while the annual FY2025 figure was $416.6 million, 28.77% down from the prior year.
  • Change in Acquisitions & Divestments reached $117.5 million in Q4 2023 per CGEM's latest filing, up from $93.8 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $132.6 million in Q4 2022 and bottomed at $4.2 million in Q1 2020.
  • Average Change in Acquisitions & Divestments over 4 years is $63.6 million, with a median of $61.4 million recorded in 2021.
  • Peak YoY movement for Change in Acquisitions & Divestments: soared 662.08% in 2022, then fell 11.4% in 2023.
  • A 4-year view of Change in Acquisitions & Divestments shows it stood at $32.9 million in 2020, then soared by 86.41% to $61.4 million in 2021, then skyrocketed by 115.96% to $132.6 million in 2022, then decreased by 11.4% to $117.5 million in 2023.
  • Per Business Quant database, its latest 3 readings for Change in Acquisitions & Divestments were $117.5 million in Q4 2023, $93.8 million in Q3 2023, and $93.6 million in Q2 2023.